Singapore to be only nation with liver cancer registry in Asia

The National Cancer Centre Singapore (NCCS), Singapore; Clinical Research Institute (SCRI) and IMS Health Asia have agreed to collaborate to develop its first Liver Cancer or Hepatocellular Carcinoma (HCC) Registry in Asia through the Asian HCC Physician Network


The date from the Registry can help policy-makers and health care professionals to formulate strategies to manage liver cancer patients. The partnership between the National Cancer Centre Singapore (NCCS), Singapore Clinical Research Institute (SCRI) and IMS Health Asia to develop first liver cancer or Hepatocellular Carcinoma (HCC) registry in Asia through the Asian HCC Physician Network is first of its kind in Asia.

This collaboration is led by Prof Pierce Chow, Senior Consultant Surgeon at NCCS, and Chairman of the Physician Network. “HCC is a leading cause of cancer-related death worldwide, and the burden of this devastating cancer is expected to increase further in coming years. The collection and analysis of epidemiologic HCC data will play a critical role in guiding future disease prevention strategies and optimizing patient management,” said Associate Prof Teoh Yee Leong, Public Health Physician and CEO, Singapore Clinical Research Institute.

Previous epidemiologic studies have highlighted striking global variations in the incidence of HCC, which is particularly high in much of East Asia and sub-Saharan Africa, and lower, but on the rise in North America and most of Europe. Although previous studies have contributed considerably to the knowledge of HCC epidemiology, there are limitations associated with the currently available data. This arose from studies performed at different times in the past, using varying methodologies, and with diverse patient populations.